Prime Editing Success – First Human Clinical Data for a New Generation of Gene Editing

The Evolution of Gene Editing

The CRISPR revolution transformed genetic medicine. For the first time, scientists could target specific locations in the genome and make changes, opening possibilities for treating diseases that were previously untouchable.

But traditional CRISPR-Cas9 has limitations. The system works by cutting the DNA double helix at a targeted location, then relying on the cell’s natural repair mechanisms to introduce desired changes. These repair processes, however, are imperfect. They can introduce unintended insertions or deletions. For some genetic corrections, the cutting approach is simply too imprecise.

Prime editing represents the next evolution—a more precise approach that can directly write new genetic sequences without cutting the double helix. Developed by David Liu’s laboratory at Harvard and the Broad Institute, prime editing uses a modified Cas9 enzyme fused to a reverse transcriptase, guided by a “prime editing guide RNA” that contains both the target address and the new sequence to be written.

Think of it as the difference between cutting a page with scissors to rearrange text versus using a word processor to directly edit a single character. Both change the document, but one offers far more precision.

First Human Proof

In May 2025, Prime Medicine announced results from the first patient ever treated with a prime editing therapy. The patient had chronic granulomatous disease (CGD), an inherited immune disorder affecting approximately one in 200,000 people.

CGD results from mutations that disable NADPH oxidase, an enzyme complex essential for white blood cells to kill certain bacteria and fungi. Without functional NADPH oxidase, patients suffer recurrent, potentially life-threatening infections and chronic inflammation that damages organs over time.

The therapy, PM359, is an ex vivo (outside the body) approach. The patient’s own blood stem cells are extracted, prime-edited in the laboratory to correct the disease-causing mutation, and then returned to the patient. Because the cells are the patient’s own, rejection isn’t an issue.

PM359 specifically targets the delGT mutation in the NCF1 gene—the most common cause of p47phox CGD, one variant of the disease. The prime editing system directly corrects this mutation, restoring the ability of white blood cells to produce functional NADPH oxidase.

Exceeding Expectations

The results exceeded therapeutic thresholds by a substantial margin.

The key measure is DHR positivity—the dihydrorhodamine assay, which measures NADPH oxidase activity in white blood cells. In CGD patients, this activity is absent or severely reduced. Experts estimate that restoring DHR positivity to 20 percent of normal would provide meaningful clinical benefit.

By day 15 after a single infusion of prime-edited cells, the patient’s DHR positivity had reached 58 percent. By day 30, it had risen to 66 percent—more than three times the therapeutic threshold.

This restoration appeared rapidly, suggesting efficient engraftment of the edited cells and robust expression of the corrected gene.

The safety profile was equally encouraging. The patient experienced no serious adverse events related to the treatment. The edited cells functioned without apparent complications.

Second Patient Confirms Results

Data from a second patient, announced in August 2025, reinforced the initial findings. This patient also showed rapid engraftment, restoration of NADPH oxidase activity well above therapeutic thresholds, and an encouraging safety profile.

Additional evidence came from inflammatory markers. Chronic inflammation is a hallmark of CGD, causing progressive organ damage even between infections. One patient had fecal calprotectin levels—a measure of intestinal inflammation—15 times the upper limit of normal at baseline.

By day 45 after treatment, calprotectin levels had returned to normal. This suggests that correcting the underlying genetic defect wasn’t just restoring immune function on laboratory tests—it was actually resolving the inflammatory pathology that makes CGD so damaging.

The Technical Advantage

Why does prime editing matter when CRISPR already exists?

Prime editing offers several advantages for certain applications. It can make any of the 12 possible single-nucleotide changes, as well as small insertions and deletions, without requiring DNA double-strand breaks. This precision is crucial for correcting point mutations—the single-letter errors that cause many genetic diseases.

Traditional CRISPR can also make corrections, but the double-strand break can lead to unintended consequences. The cell’s repair mechanisms sometimes introduce errors. In some cell types, the cutting can trigger cell death or chromosomal abnormalities.

Prime editing’s write-without-cutting approach avoids these issues. While no technology is perfect, prime editing offers a complementary tool for cases where traditional CRISPR isn’t ideal.

Strategic Realities

Despite the breakthrough results, Prime Medicine announced it would not independently continue developing the CGD program. The company is exploring options for the therapy’s continued development with partners while focusing its resources on other programs, including treatments for Wilson’s disease and alpha-1 antitrypsin deficiency.

This reflects the challenging economics of rare disease therapy development rather than any problem with the science. CGD affects relatively few patients, and rare disease drug development requires substantial investment regardless of patient numbers. Companies must make difficult decisions about where to concentrate resources.

The scientific proof of concept, however, stands regardless of commercial decisions. Prime editing works in humans. The first-ever prime editing therapy safely corrected a genetic disease and exceeded therapeutic expectations.

Implications for Genetic Medicine

The CGD results establish prime editing as a clinically viable approach. This has implications extending far beyond one rare disease.

Thousands of genetic diseases are caused by point mutations—single-letter errors in DNA. Many of these are theoretically correctable by prime editing with appropriate targeting. Conditions that have resisted other approaches might become addressable.

The ex vivo approach demonstrated here—editing cells outside the body before returning them—is one application model. In vivo approaches, where prime editing is delivered directly to tissues inside the patient, are also in development for conditions where extracting and returning cells isn’t practical.

The liver is a particularly attractive target for in vivo prime editing because it’s accessible to lipid nanoparticle delivery systems and is the site of many metabolic diseases. Prime Medicine’s continuing programs focus on this approach.

What This Means

The first prime editing success doesn’t mean genetic diseases are solved. Each condition requires its own development program. Safety and efficacy must be established for each application. Manufacturing, delivery, and regulatory approval present ongoing challenges.

But proof of concept matters enormously in medicine. Once something is shown to be possible, the path forward becomes clearer. Prime editing in humans isn’t theoretical anymore—it’s demonstrated.

For patients with genetic diseases caused by point mutations, this represents meaningful progress. A technology capable of precisely correcting single DNA letters now exists and has been shown to work safely in humans.

The era of truly precise genetic medicine has begun.

Sources

1. Prime Medicine Press Release. “Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359.” May 19, 2025. https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-breakthrough-clinical-data-showing

2. Prime Medicine Press Release. “Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates.” August 2025. https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-reports-second-quarter-2025-financial-results-and

3. CRISPR Medicine News. “First-Ever Prime-Editing Therapy Shows Safety and Efficacy in Patient With Chronic Granulomatous Disease.” 2025. https://crisprmedicinenews.com/news/first-ever-prime-editing-therapy-shows-safety-and-efficacy-in-patient-with-chronic-granulomatous-dis/